Furiex Pharma target raised to $137 at Ladenburg after positive data

Ladenburg Thalmann hikes its price target for Furiex Pharmaceuticals (FURX +127.8%) to $137 from $57 after the drug developer's Eluxadoline experimental drug to treat a form of irritable bowel syndrome met main goals in a late-stage study.

Alogliptin, now approved in the U.S., Japan and Europe, represents another valuable asset, the firm says, expecting U.S. and E.U. revenues will start to impact the level of royalty revenues FURX receives during 2014; the company is entitled to tiered royalties of 8%-12% and 4%-8% in the U.S. and Europe/Japan, respectively (Briefing.com).

Mizuho does not consider positive data yesterday for FURX as a negative for Salix Pharma's (SLXP +2.5%) Xifaxan; a large population means room for two products, and different MOA and response rates mean variable patient responses, it says.

Comments (1)
  • Bret Jensen
    , contributor
    Comments (14476) | Send Message
    It is Always your smallest positions that produce the most gains....think it is murphy's law applied to investing................


    4 Feb 2014, 04:14 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs